Sanofi Presents Results of Tolebrutinib in a P-IIb LTS for Relapsing Forms of Multiple Sclerosis at ECTRIMS 2021

Shots:

• The P-IIb LTS part A assesses tolebrutinib (5/15/30/60mg/day) in patients with RMS and in Part B, where all participants switched to the 60mg
• The study demonstrated a reduction in MS disease activity as MRI and showed a favorable 1yrs. tolerability. “Mean EDSS scores across treatment groups ranged from 2.18 to 2.65 at baseline and remained relatively stable over 48 weeks. For the 60/60mg treatment group, mean (SD) score was 2.65 (1.22) at baseline and 2.45 (1.31) at Week 48; low MRI lesion activity in patients who started on or switched to 60mg. 98% of patients remained on treatment in P-IIb extension study @48wks.
• @48wks. of the extension study, low Gd-enhancing lesions (<0.4) in the 60/60mg arm. Additionally, data from in vitro studies in human microglia extended previous observations that BTK-dependent inflammatory signaling can be modulated by tolebrutinib

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Medcity News